Onchocerciasis Drug Discovery: In Vitro Evaluation of FDA-Approved Drugs against

FDA-approved drugs O. gutturosa anthelmintics drug discovery motility and MTT inhibition onchocerciasis

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
31 Jan 2024
Historique:
received: 16 11 2023
revised: 18 01 2024
accepted: 25 01 2024
medline: 24 2 2024
pubmed: 24 2 2024
entrez: 24 2 2024
Statut: epublish

Résumé

Onchocerciasis treatment and control relies mainly on the use of ivermectin which has high activity against the microfilarial stage of

Identifiants

pubmed: 38399264
pii: pharmaceutics16020210
doi: 10.3390/pharmaceutics16020210
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Suzanne Gokool (S)

Tropical Parasitic Diseases Unit, Northwick Park Institute for Medical Research, Watford Road, Harrow, London HA1 3UJ, UK.

Simon Townson (S)

Tropical Parasitic Diseases Unit, Northwick Park Institute for Medical Research, Watford Road, Harrow, London HA1 3UJ, UK.

Andrew Freeman (A)

Tropical Parasitic Diseases Unit, Northwick Park Institute for Medical Research, Watford Road, Harrow, London HA1 3UJ, UK.

Jadzia Siemienski-Kleyn (J)

Tropical Parasitic Diseases Unit, Northwick Park Institute for Medical Research, Watford Road, Harrow, London HA1 3UJ, UK.

Jakub Zubrzycki (J)

Tropical Parasitic Diseases Unit, Northwick Park Institute for Medical Research, Watford Road, Harrow, London HA1 3UJ, UK.

Senyo Tagboto (S)

Tropical Parasitic Diseases Unit, Northwick Park Institute for Medical Research, Watford Road, Harrow, London HA1 3UJ, UK.

Marc P Hübner (MP)

Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.
German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, 53127 Bonn, Germany.

Ivan Scandale (I)

Drugs for Neglected Diseases Initiative, 1202 Geneva, Switzerland.

Classifications MeSH